From msnbc.msn.com
()
Zetia
Zetia is a new cholesterol-lowering drug. read news about Zetia and reviews of the medical benefits, possible side effects, and Congressional hearings about Zetia.
The study of Vytorin, manufactured by Merck & Co Inc., and Zetia, manufactured by Schering-Plough Corp., was closely watched because the drugs have been prescribed to millions of people and generated about $5 billion in sales despite limited proof of ...
- Merck, Schering-Plough Sink on Vytorin (rss.topix.net)
- Merck, Schering-Plough shares plummet on Vytorin study (rss.topix.net)
Schering-Plough has a joint venture with Merck & Co. that markets Vytorin and Zetia. Preliminary results of the Enhance study were released in January, ...
From news.google.com via
Google News.
()
- Schering-Plough cutting staff, costs (rss.topix.net)
Isis Pharmaceuticals will delay submitting final results from a late-stage study of its cholesterol drug after U.S. health regulators asked for additional cancer-related data from two preclinical trials.
More perspectives...
From news.search.yahoo.com via
Yahoo News.
()
TORONTO - Canada's ban on direct-to-consumer drug advertising probably saved Canadians with high cholesterol and their drug plans $150 million in 2006 alone, suggests a new study comparing sales patterns of a controversial cholesterol lowering drug in the United States and Canada.
More perspectives...
From news.search.yahoo.com via
Yahoo News.
()
The Food and Drug Administration has rejected one of Merck's new blockbuster drug, a cholesterol-lowering medicine Cordaptive or MK-0524A.
From news.search.yahoo.com via
Yahoo News.
()
- FDA Rejects Merck's Cordaptive (whatreallyhappened.com)
- Study: Cholesterol-lowering drug does little (news.search.yahoo.com)
Merck's and Schering-Plough's anti-cholesterol drug Vytorin Pharmaceuticals, shows their cholesterol drug Vytorin, produced in conjunction with Merck & Co. The FDA approved Vytorin 23 July 2004. According to Schering-Plough and Merck, Vytorin is the only drug that treats both means the body has...
From news.search.yahoo.com via
Yahoo News.
()
- Merck, Schering skid on Vytorin data (rss.topix.net)
Biotechnology companies Isis Pharmaceuticals Inc. and Genzyme Corp. said Friday approval of their cholesterol drug candidate mipomersen will face at least a one-year delay, now that the Food and Drug Administration has asked for more study data.
More perspectives...
From news.search.yahoo.com via
Yahoo News.
()
The makers of popular cholesterol drugs Vytorin and Zetia are being sued in at least four states over allegations that Merck & Co. and Schering-Plough Corp. misled consumers into ...
From msnbc.msn.com
()
- Drug stocks mixed; Schering-Plough gains (rss.topix.net)
- Schering-Plough mit deutlichem Gewinnrckgang nach Sonderbelastungen (finanznachrichten.de)
- Schering-Plough profit slides 48% (rss.topix.net)
The Food and Drug Administration is expected to hand down its decision next week on Cordaptive, Merck's new drug designed to raise HDL, or good cholesterol. ...
More perspectives...
From news.google.com via
Google News.
()
Based in New Jersey, USA, Schering-Plough is a pharmaceutical company that employs some 55,000 people, operating in more than 140 countries worldwide. Conducting research in the areas of cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology...
From cnn.com
()
- Schering-Plough Makes Changes After Negative Studies On Vytorin (clipsyndicate.com)
- Pops & Drops: Schering-Plough, MEMC Electronics... (news.google.com)
